Betalin Therapeutics
Tissue Engineering for Insulin Therapy Alternative
StartupBetalin Therapeutics is a Jerusalem-based startup in the Health Tech & Life Sciences sector, established in 2015. Tissue Engineering for Insulin Therapy Alternative. The company has raised a total of $11.06M across 6 funding rounds, currently at the A stage. Betalin Therapeutics was founded by Shuki Joshua Hershcovich and Shay Hershcovich. Key investors include Together We Invest, European Innovation Council (EIC), Undisclosed Investor(s). The company has 1-10 employees. Core technologies: Materials & Substances, Implants, Biologicals, Cells.
With $11.06M in total funding, Betalin Therapeutics is a A-stage company operating in Health Tech & Life Sciences. The company follows a B2B2C business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageA
- ProductClinical Trial
- ModelB2B2C
- Employees1-10
- HQJerusalem
- DistrictCenter District,Jerusalem District
- Last RoundUndisclosed
- Together We InvestLead
- European Innovation Council (EIC)
- Undisclosed Investor(s)
Shuki Joshua HershcovichCo-founder & Chairman
Shay HershcovichCo-founder, Marketing Manager & Director
16 articles covered by sources including www.ynetnews.com,
www.jpost.com,
www.sponser.co.il,
www.calcalistech.com,
trailer.web-view.net.
What does Betalin Therapeutics do?
Betalin Therapeutics seeks to eliminate the need for insulin injections and glucose testing in diabetes patients with its proprietary transplanted Engineered Micro Pancreas (EMP). The EMP technology helps create connective tissue that enables the body's beta cells to function properly and produce adequate and functional insulin. Betalin Therapeutics licensed the novel EMP technology developed at the Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.
How much funding has Betalin Therapeutics raised?
Betalin Therapeutics has raised $11.06M in total funding across 6 rounds. The company is currently at the A stage. Key investors include Together We Invest, European Innovation Council (EIC), Undisclosed Investor(s).
Who founded Betalin Therapeutics?
Betalin Therapeutics was founded in 2015 by Shuki Joshua Hershcovich (Co-founder & Chairman), Shay Hershcovich (Co-founder, Marketing Manager & Director).
What sector is Betalin Therapeutics in?
Betalin Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Biomaterials & Tissue Engineering, with core technologies in Materials & Substances, Implants, Biologicals, Cells. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Patients.
Where is Betalin Therapeutics located?
Betalin Therapeutics is based in Jerusalem Bio Park (JBP) Minrav Bldg, Center District,Jerusalem District.